Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27865960 | 0.81 | CA1 (0.44) | CA1CA2CA12CA7CA13 | |
| SCHEMBL21667232 | 0.77 | CA1 (0.50) | CA1CA2CA12CA7CA13 | |
| SCHEMBL4870631 | 0.77 | RECQL (0.50) | CA1CA2CA12CA7CA13 | |
| SCHEMBL15152520 | 0.70 | CA2 (0.42) | CA1CA2CA12CA7CA13 | |
| SCHEMBL6573700 | 0.69 | ALDH1A1 (0.42) | CA1CA2CA12CA7CA9 | |
| SCHEMBL15152532 | 0.69 | CA1 (0.41) | CA1CA2CA12CA7CA13 | |
| SCHEMBL15152530 | 0.69 | CA1 (0.41) | CA1CA2CA12CA7CA13 | |
| SCHEMBL15475636 | 0.69 | RECQL (0.54) | CA1CA2ALDH1A1TSHRGAA | |
| Lithium Ion SCHEMBL17456396 | 0.69 | RECQL (0.48) | CA1CA2ALDH1A1TSHRGAA | |
| SCHEMBL15173534 | 0.68 | CA1 (0.41) | CA1CA2CA12CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872122-B2 | Process for making Biolimus A9 | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. (TW) | 2011-01-18 | — | — | US | claimed |
| US-20090292118-A1 | Process for making Biolimus A9 | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. (TW) | 2009-11-26 | — | — | US | claimed |
| US-7872122-B2 | Process for making Biolimus A9 | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. (TW) | 2011-01-18 | — | — | US | disclosed |
| US-20090292118-A1 | Process for making Biolimus A9 | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. (TW) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292118-A1 | Process for making Biolimus A9 | RICTOR, MRPL9, RPS9 | CA1 4808/4885CA2 4441/4885CA12 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.